Tech Company Financing Transactions

ILiAD Biotechnologies Funding Round

Network-1 Technologies, SDS Capital Partners and JEMS Venture Capital participated in a $20 million Series C funding round for ILiAD Biotechnologies. The round was announced on 12/20/2018.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

230 East 15th St. 1-A
New York, NY 10003
USA

Phone

(954) 336-0777

Website

www.iliadbio.com

Email Address

[email protected]

Overview

ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently in Phase 2 and has successfully completed two Phase 1 human clinical trials.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Keith Rubin

        

Chief Financial Officer

Walter Greenblatt

        

Chief Operating Officer

Ken Solovay

        

Controller

James Ramadei

        

General Manager

Marcel Thalen

        

Vice President

Stanley Kim

        

Browse more venture capital transactions:

Prev: 12/20/2018: Malta venture capital transaction
Next: 12/20/2018: Dataiku venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary